|
Novacyt SA - Paris-based biotechnology group focused on clinical diagnostics - Reports conclusion of the Health & Safety Executive prosecution announced back in January against its non-trading subsidiary, Lab 21 Healthcare Ltd. The case relates to the use of biological agents at Lab 21’s site in Axminster, Devon. Notes that Lab 21 pleaded guilty back in March to health and safety charges relating to the operation at the site between June 2018 and April 2019. Says a sentencing hearing took place on Thursday, with the court granting full recognition for an early guilty plea, with Lab 21 ordered to pay a £52,000 fine. Novacyt says the amount will be paid through existing cash resources and does not materially affect its financial position. Adds that the process is now concluded, with no further liability or legal action expected. Current stock price: 42.48, up 4.2% on Friday morning in London 12-month change: down 39% Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
